GLP1R and Insulin resistance: No differences were observed in fasting levels of blood glucose (Fig. 1i), but levels of insulin (Fig. 1j) and insulin sensitivity, as estimated by homeostatic model assessment for insulin resistance (HOMA-IR) (Fig. 1k), were equally improved by treatment with acyl-GLP-1 and the co-therapy, and without difference between WT and Vgat-Gipr KO mice.